FULC (Fulcrum Therapeutics) EPS (Basic): $-1.21 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FULC Fulcrum Therapeutics Inc FULC
44 GF Score
Price $3.73
GF Value $32.03
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Fulcrum Therapeutics EPS (Basic)?

Fulcrum Therapeutics FULC +0.95% 44 EPS (Basic) is $-1.21 as of Jun. 2026. GuruFocus rates FULC with a GF Score™ of 44/100 and a GF Value™ of $32.03 (Possible Value Trap). The stock has 1 warning sign investors should review.

Fulcrum Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was $-0.34. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.21.

Fulcrum Therapeutics's EPS (Diluted) for the three months ended in Jun. 2026 was $-0.34. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.21.

Fulcrum Therapeutics's EPS without NRI for the three months ended in Jun. 2026 was $-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -1.09.

During the past 3 years, the average EPS without NRI Growth Rate was 21.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 31.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Fulcrum Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 61.90% per year. The lowest was -6.40% per year. And the median was 19.25% per year.

Fulcrum Therapeutics  (NAS:FULC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Fulcrum Therapeutics EPS (Basic) Related Terms

Fulcrum Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Fulcrum Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulcrum Therapeutics EPS (Basic) Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -2.29 -2.44 -1.59 -0.16 -1.18

Fulcrum Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.31 -0.31 -0.25 -0.34
FULC
44GF Score
Fulcrum Therapeutics Inc FULC
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulcrum Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Fulcrum Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-74.88-0)/63.355
=-1.18

Fulcrum Therapeutics's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-26.179-0)/76.264
=-0.34

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.21 mean?
Fulcrum Therapeutics (FULC) has a EPS (Basic) of $-1.21 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Fulcrum Therapeutics and its competitors.
Is Fulcrum Therapeutics' EPS (Basic) too high?
Fulcrum Therapeutics' current EPS (Basic) is $-1.21. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' EPS (Basic) compare to AGEN and IRD?
Fulcrum Therapeutics' EPS (Basic) of $-1.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Fulcrum Therapeutics and its competitors. Fulcrum Therapeutics's current EPS (Basic) is $-1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current EPS (Basic) is $-1.21. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current EPS (Basic) is $-1.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulcrum Therapeutics (FULC) Overvalued in 2026?

Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued. The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03. GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.

Key valuation signals for FULC:

  • EPS (Basic): $-1.21
  • GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulcrum Therapeutics Business Description

Address 26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score

Get the complete analysis for FULC

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.73
Price
$32.03
GF Value